Receiving an iron infusion every one to two years could help people with heart failure avoid being admitted to hospital, new research suggests. Nearly one million people in the UK are living with ...

Intravenous (IV) iron use overall is associated with a “very low” risk for anaphylaxis, but iron dextran and ferumoxytol carry an increased risk relative to iron sucrose, according to new research.

Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and ...

Repeated intravenous (IV) administration of iron reduced the risk of hospitalization for heart failure and cardiovascular death in people with heart failure and iron deficiency, according to a ...

Please provide your email address to receive an email when new articles are posted on . IV iron is the most cost-effective option for women with iron deficiency anemia and heavy menstrual bleeding.

To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who ...

This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb ≤ 105 g/L, serum ferritin ≤ 450 pmol/L or ≤ 675 pmol/L with transferrin ...

Pharmacosmos A/S, a Denmark-based industry leader for developing and marketing medicines for the treatment of iron deficiency, said its Monofer, a new generation of innovative intravenous iron for the ...

A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in Blood ...